Asset Details
Do you wish to reserve the book?
Mendelian randomization does not support serum calcium in prostate cancer risk
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mendelian randomization does not support serum calcium in prostate cancer risk
Do you wish to request the book?
Mendelian randomization does not support serum calcium in prostate cancer risk
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mendelian randomization does not support serum calcium in prostate cancer risk
2018
Overview
Purpose
Observational studies suggest that dietary and serum calcium are risk factors for prostate cancer. However, such studies suffer from residual confounding (due to unmeasured or imprecisely measured confounders), undermining causal inference. Mendelian randomization uses randomly assigned (hence unconfounded and pre-disease onset) germline genetic variation to proxy for phenotypes and strengthen causal inference in observational studies. We tested the hypothesis that serum calcium is associated with an increased risk of overall and advanced prostate cancer.
Methods
A genetic instrument was constructed using five single-nucleotide polymorphisms robustly associated with serum calcium in a genome-wide association study (
n
≤ 61,079). This instrument was then used to test the effect of a 0.5 mg/dL increase (1 standard deviation, SD) in serum calcium on risk of prostate cancer in 72,729 men in the PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) Consortium (44,825 cases, 27,904 controls) and risk of advanced prostate cancer in 33,498 men (6,263 cases, 27,235 controls).
Results
We found weak evidence for a protective effect of serum calcium on prostate cancer risk (odds ratio [OR] per 0.5 mg/dL increase in calcium: 0.83, 95% CI 0.63–1.08;
p
= 0.12). We did not find strong evidence for an effect of serum calcium on advanced prostate cancer (OR per 0.5 mg/dL increase in calcium: 0.98, 95% CI 0.57–1.70;
p
= 0.93).
Conclusions
Our Mendelian randomization analysis does not support the hypothesis that serum calcium increases risk of overall or advanced prostate cancer.
Publisher
Springer Science + Business Media,Springer International Publishing,Springer Nature B.V
Subject
/ Calcium, Dietary - adverse effects
/ Genome-wide association studies
/ Genome-Wide Association Study
/ Genomes
/ Humans
/ Male
/ Mendelian Randomization Analysis
/ Oncology
/ Polymorphism, Single Nucleotide
/ Prostatic Neoplasms - epidemiology
/ Prostatic Neoplasms - etiology
